Buy Novartis Stock in 2026: Share Price, Dividend and Analysis
Looking to buy Novartis stock? Switzerland’s largest pharmaceutical company, focused solely on patented medicines since the Sandoz spin-off, combines double-digit growth, a dividend raised every year and mega-cap scale. This page covers its results, payout policy, strengths and risks, and how to buy the stock from France.
Novartis Share Price
The stock is listed on the Swiss stock exchange (NOVN) and as an ADR in New York (NVS). You can check the live quote with your broker or on the leading financial platforms; the share price has risen sharply over the past two years, driven by results and the re-rating of the pharmaceutical sector.
Before you decide, also look at how Newron Pharmaceuticals stock is performing.
Novartis Stock Profile
| Company | Novartis AG |
| Market | SIX Swiss Exchange (NOVN); NYSE ADR (NVS) (checked on 10/27/2026) |
| Ticker / Symbol | NOVN (Zurich) · NVS (NYSE) |
| ISIN | CH0012005267 |
| Headquarters | Basel, Switzerland |
| Sector | Pharmaceuticals: patented medicines (cardiology, immunology, oncology…) |
| Trading currency | Swiss franc (CHF) in Zurich; US dollar for the ADR (accounts reported in US dollars) |
| Financial year-end | December 31 |
| PEA eligibility | No (issuer domiciled outside the EU/EEA: Switzerland) |
About Novartis: Business and Markets
A pure-play pharmaceutical company
Formed in 1996 from the merger of Ciba-Geigy and Sandoz, two Basel chemical companies with roots going back to the 19th century, Novartis has gradually shed everything that was not innovative medicine: consumer health was sold, Alcon was spun off, and above all the Sandoz generics subsidiary was spun off at the end of 2023. The group, led by Vasant Narasimhan, employs about 75,000 people and draws most of its growth from a portfolio of major medicines in cardiology, immunology and oncology.
A pipeline backed by strong franchises
Treatments such as Entresto (heart failure), Cosentyx (immunology) and Kisqali (breast cancer) have become multibillion-dollar franchises; the key strategic question is the handover to new products — cell and gene therapies, radioligands — as Entresto has faced generic competition in the United States since 2025. This renewal determines how sustainable growth will be.
Swiss roots, global listing
Novartis remains one of Europe’s largest companies by market value and a pillar of the Swiss indices. French individual investors can access it via the Swiss franc line in Zurich or, more simply, via the ADR listed in New York in US dollars — each ADR representing one ordinary share.
Novartis Results and Financial Data
Consolidated accounts for the last three financial years ended December 31:
| Indicator | FY 2023 | FY 2024 | FY 2025 | Year-on-year change |
|---|---|---|---|---|
| Revenue | $46,660M | $51,722M | $56,674M | +9.6% |
| Net income | $14,850M | $11,941M | $13,984M | +17.1% |
Amounts in millions of US dollars. Source: S&P Global Market Intelligence via StockAnalysis, consolidated accounts; data accessed on 10/27/2026. 2023 net income includes exceptional items related to the Sandoz spin-off.
The operating trajectory is remarkably steady: two consecutive years of double-digit revenue growth, a net margin of around 25%, and net income rising again in 2025 after a 2024 marked by post-spin-off accounting normalization. Entresto’s loss of exclusivity in the United States is the main headwind identified going forward; offsetting it with new products is the key metric to track.
Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →Novartis Stock Dividend
Novartis follows a progressive dividend policy, raising its payout year after year since the group was created, with comfortable coverage. The yield is around 2% at the current share price ($3.08 per ADR at the last ex-dividend date in March 2026, according to data compiled by StockAnalysis) — a modest level, but backed by steady growth in the amount paid out.
Should You Buy Novartis Stock in 2026?
Strengths:
- A successful focus on innovative medicines: double-digit growth on a streamlined business.
- A growing dividend covered by large profits, and the defensive profile of the healthcare sector.
- Global scale and liquidity: a mega-cap that is easy to buy and sell.
Points to watch:
- Entresto’s loss of exclusivity in the United States: the biggest sales contributor now faces generics.
- The valuation is back at a high multiple (nearly 30 times earnings) after the share price rise.
- Not eligible for the PEA, with Swiss franc/US dollar currency exposure for euro-based investors.
- Ongoing sector risks: US pricing decisions, clinical trials, competition.
Novartis is a core portfolio healthcare stock: quality and consistency now come at a high price, and the stock suits a long-term investor willing to pay a high multiple for strong visibility — with a consistent weighting within an internationally diversified portfolio.
Fundamental and Technical Analysis of Novartis Stock
Fundamental analysis
Three indicators drive the investment case: how quickly new products absorb the Entresto patent expiry, a continuously improving operating margin, and free cash flow generation that funds the dividend, buybacks and partnerships. Quarterly results detail growth by product; check the latest published reports for the state of the pipeline.
Technical analysis
The stock is in a medium-term uptrend, near the top of its 52-week range: quarterly results and pipeline announcements trigger sharp moves, and psychological levels provide the usual reference points; our technical analysis guide explains these tools to help with execution.
How to Buy Novartis Stock
- Choose a broker that gives access to the Swiss stock exchange or the NYSE — compare fees in our selection of the best online brokers.
- Open a standard brokerage account: unlike European stocks, the Swiss stock is not eligible for the PEA, so a brokerage account is required.
- Fund the account, taking Swiss franc or US dollar conversion fees into account.
- Place your order on NOVN in Zurich or NVS in New York, preferably as a limit order; the full method is explained in our guide to buying shares.
Trading hours
The SIX Swiss Exchange trades from 9:00 a.m. to 5:30 p.m. Swiss time (the same as France); the NVS ADR trades on the NYSE from 3:30 p.m. to 10:00 p.m. Paris time. The W-8BEN form reduces US withholding tax on ADR income.
Taxation
Swiss dividends are subject to a 35% Swiss withholding tax, and the excess above the treaty limit can be reclaimed from the Swiss tax authorities; capital gains are subject to the 30% PFU flat tax in a standard securities account.
Novartis Stock FAQ
What is the difference between NOVN and NVS?
NOVN is the Swiss franc line listed in Zurich; NVS is the ADR listed on the NYSE in US dollars, representing one share. Both give exposure to the same stock, at different hours and in different currencies.
Can Novartis stock be held in a PEA?
No. The registered office is in Switzerland, outside the European Union and the European Economic Area: the stock is held in a standard brokerage account.
What dividend does Novartis pay?
A growing annual dividend, raised every year, with a yield of about 2% at the current share price; check the amount in Swiss francs in the general meeting proposal for each financial year.
What were Novartis’s 2025 results?
Revenue of $56.7 billion (+9.6%) and net income of $14.0 billion (+17.1%), according to the consolidated accounts.
What is the main risk for Novartis?
The arrival of Entresto generics in the United States: the ability of new medicines to offset this loss of sales will determine the earnings trajectory.
Disclaimer: this content is for information only and does not constitute investment advice. Investing in the stock market carries a risk of capital loss; past performance is not a reliable indicator of future results.
